EGFR and pancreatic ductal adenocarcinoma: For example, researchers [125] used EGFR-EDV-Dox as a drug delivery system to conduct a phase I clinical trial (NCT02766699) on pancreatic ductal adeno-carcinoma and Glioblastoma Multiforme (GBM).